New trial aims to match diabetes drugs to patients for better heart and kidney protection
NCT ID NCT07594145
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 2 trial will test two drugs, finerenone and sotagliflozin, in 57 people with type 1 diabetes who are at risk for heart and kidney problems. The goal is to see if matching the right drug to each person's specific diabetes subtype can improve early signs of heart and kidney health. The study will measure changes in urine protein and a heart stress marker over 26 weeks.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
finerenone and sotagliflozin
What this could lead to
If successful, this trial could show that matching specific diabetes subtypes to targeted drugs helps protect the heart and kidneys in people with type 1 diabetes.
What could go wrong
This is a small, early-phase trial (57 people) testing short-term effects. The drugs may not work as hoped, and side effects are possible. Results may not apply to everyone with type 1 diabetes.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TYPE 1 DIABETES are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Oregon Health & Science University
Portland, Oregon, 97239, United States
Contact Phone: •••-•••-••••
Contact
Contact
Contact
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
University of Michigan
Ann Arbor, Michigan, 48109, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact